BioArctic: Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease filed in South Korea

STOCKHOLM, June 8, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab

Related Keywords

Canada ,Uppsala ,Uppsala Lan ,Sweden ,Japan ,United Kingdom ,Zeiten ,Mecklenburg Vorpommern ,Germany ,Stockholm ,South Korea ,China ,Swedish ,Great Britain ,Stefan Klotter ,Oskar Bosson ,National Institutes Of Health ,Alzheimer Network Trials Unit ,Vp Communications ,National Institute On ,Washington University School Of Medicine ,Ministry Of Food ,Drug Administration ,Advisory Committee ,Uppsala University ,Alzheimer Clinical Trial Consortium ,Nasdaq Stockholm ,Drug Safety ,Brand Name ,Biologics License Application ,Priority Review ,Prescription Drug User Fee Act ,Innovative Licensing ,Access Pathway ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Commercialization Agreement ,Nasdaq Stockholm Large Cap ,Authorization Application ,Stabile Ertr ,Chart Profi Stefan Klotter ,Blue Chips ,Bioarctic ,Marketing ,Authorization ,Application ,Lecanemab ,Treatment ,Early ,Lzheimer ,Disease ,Iled ,Mouth ,Korea ,